UBS Group AG Trims Position in Eton Pharmaceuticals, Inc. $ETON

UBS Group AG decreased its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 42.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 126,674 shares of the company’s stock after selling 93,687 shares during the period. UBS Group AG’s holdings in Eton Pharmaceuticals were worth $2,142,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Opaleye Management Inc. lifted its stake in shares of Eton Pharmaceuticals by 0.3% during the second quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock valued at $40,755,000 after buying an additional 7,930 shares during the period. Vanguard Group Inc. lifted its stake in shares of Eton Pharmaceuticals by 2.4% during the third quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock valued at $29,208,000 after buying an additional 31,942 shares during the period. Cannell Capital LLC lifted its stake in shares of Eton Pharmaceuticals by 17.3% during the third quarter. Cannell Capital LLC now owns 455,405 shares of the company’s stock valued at $9,896,000 after buying an additional 67,230 shares during the period. Millennium Management LLC lifted its stake in shares of Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after buying an additional 217,042 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Eton Pharmaceuticals by 44.9% during the third quarter. JPMorgan Chase & Co. now owns 351,417 shares of the company’s stock valued at $7,636,000 after buying an additional 108,837 shares during the period. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Performance

NASDAQ:ETON opened at $32.40 on Thursday. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. The company has a market cap of $887.44 million, a P/E ratio of -462.79 and a beta of 0.82. Eton Pharmaceuticals, Inc. has a fifty-two week low of $13.09 and a fifty-two week high of $35.66. The firm’s 50 day moving average is $26.59 and its two-hundred day moving average is $20.03.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The company had revenue of $24.27 million for the quarter, compared to analysts’ expectations of $22.31 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%. Analysts expect that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ETON. HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, May 15th. B. Riley Financial upped their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Zacks Research downgraded shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 17th. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Finally, Wall Street Zen raised shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $41.00.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, insider David Krempa sold 42,797 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the transaction, the insider owned 25,249 shares of the company’s stock, valued at $843,064.11. This trade represents a 62.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 100,000 shares of company stock worth $3,229,921 over the last quarter. Company insiders own 16.49% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.